Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation.
In 2009 we just had a roadmap, ideas and plans to develop a global molecular diagnostics company in the field of Next Generation Sequencing. We managed to find out our direction and have become a significant player on the HLA-typing market.
2012Seed Funding Milestone, Omixon launches Target software.
2014 MayOmixon announces exclusive license with the Children’s Hospital of Philadelphia for Holotype HLA, Raises Capital, Launches US Office.
2014 SeptOmixon launches Holotype HLA via Early Access, first NGS-based HLA typing product.
2015 OctOmixon closes Early Access Program, presents early data at ASHI.
Omixon announces Major Tender Victory in France.
2016 FebOmixon announces Dimitri Monos as Chairman of Scientific Advisory Board.
Omixon announces CE Mark for Holotype HLA.
2017 Omixon launches HLA Explore for HLA Researchers.
Omixon launches Monotype ABO molecular typing kit.
Our Executive Team have spent more than a decade leading Software, NGS and genomics companies. Our Research and Development Team have a mixture of experience in all aspects of molecular diagnostics, with experts in software development, bioinformatics and genomics. Professor Dimitri Monos who serves as Chairman of the Scientific Advisory Board was one of the pioneers of NGS for HLA, and the inventor of the Holotype. Our major collaborators and key opinion leaders in the HLA community have provided the highest level of leadership within the community for several decades and Omixon has evolved into a global molecular diagnostics company that currently focuses on driving the adoption of NGS in the clinic with Holotype HLA, the world’s leading NGS-based HLA genotyping Assay and Software product.